• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Prevacid (lansoprazole) delayed-release capsules and orally disintegrating tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010

 

Summary View

 

Use in Specific Populations
  • Prevacid is not effective in patients with symptomatic GERD age 1 month to less than 1 year of age
Patient Counseling Information
  • Prevacid SoluTab delayed-release orally disintegrating tablets should not be broken or cut